TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Insider Buys $79,650.00 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) insider Sean Murphy purchased 15,000 shares of the stock in a transaction that occurred on Monday, January 27th. The stock was bought at an average price of $5.31 per share, with a total value of $79,650.00. Following the completion of the acquisition, the insider now owns 182,732 shares in the company, valued at $970,306.92. This represents a 8.94 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

TriSalus Life Sciences Price Performance

Shares of TriSalus Life Sciences stock opened at $5.11 on Friday. The business has a 50-day moving average of $4.57 and a 200-day moving average of $4.75. The company has a market capitalization of $155.80 million, a PE ratio of -2.05 and a beta of 0.51. TriSalus Life Sciences, Inc. has a 1-year low of $3.50 and a 1-year high of $10.42.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Walleye Capital LLC bought a new stake in shares of TriSalus Life Sciences in the 3rd quarter valued at approximately $66,000. Virtu Financial LLC acquired a new position in TriSalus Life Sciences in the third quarter worth $92,000. Vestcor Inc bought a new stake in TriSalus Life Sciences during the third quarter valued at $108,000. MSD Partners L.P. acquired a new stake in shares of TriSalus Life Sciences during the third quarter worth $184,000. Finally, Geode Capital Management LLC lifted its position in shares of TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after buying an additional 62,542 shares during the last quarter. Institutional investors own 2.58% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on TLSI. Canaccord Genuity Group lowered their price target on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a report on Friday, November 15th. Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Cantor Fitzgerald began coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target for the company. Northland Securities assumed coverage on TriSalus Life Sciences in a report on Friday, October 25th. They issued an “outperform” rating and a $12.50 price target for the company. Finally, Roth Mkm restated a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Seven equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, TriSalus Life Sciences currently has an average rating of “Buy” and a consensus price target of $11.79.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.